Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus

Affiliations

• ¹ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany tobias.alexander@charite.de.
• ² Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, an Institute of the Leibniz Association, Autoimmunology Group, Berlin, Germany.
• ³ Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
• ⁴ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.